Skip to main content

Great Point Partners LLC

SEC CIK
0001281446
Latest filing
Aug 14, 2026

Holdings in Q2 2024

Holdings as of Jun 30, 2024, filed Aug 14, 2024. Long positions only; changes compare share counts with Q1 2024.

Institution overview
Positions
33
−2 vs. Q1 2024
Portfolio value
$522.0M
−$119.6M (−18.6%) vs. Q1 2024
Filed
Aug 14, 2024
SEC
Holdings of Great Point Partners LLC in Q2 2024
SecurityClassSharesValue% of portfolioShare changeActionHistory
URGNUroGen Pharma Ltd.COM2,906,259$48.8M9.3%+285,714+10.9%AddedHistory
NGNENeurogene Inc.COM1,004,291$36.5M7.0%00.0%UnchangedHistory
ABVXAbivax S.A.SPONSORED ADS2,472,188$32.7M6.3%−16,295−0.7%ReducedHistory
MRUSMerus N.V.COM523,288$31.0M5.9%+300,000+134.4%AddedHistory
PLRXPliant Therapeutics, Inc.COM2,636,864$28.3M5.4%+785,000+42.4%AddedHistory
ACLXArcellx, Inc.COMMON STOCK492,000$27.2M5.2%+192,000+64.0%AddedHistory
DVAXDynavax Technologies CorpCOM NEW2,374,000$26.7M5.1%+1,109,080+87.7%AddedHistory
EOLSEvolus, Inc.COM2,451,772$26.6M5.1%+1,772+0.1%AddedHistory
CYTKCytokinetics IncCOM NEW474,202$25.7M4.9%+272,000+134.5%AddedHistory
DNTHDianthus Therapeutics, Inc.COM757,929$19.6M3.8%+132,929+21.3%AddedHistory
INSMINSMED IncCOM PAR $.01250,000$16.8M3.2%−525,585−67.8%ReducedHistory
ZURAZura Bio LtdCLASS A ORD SHS4,642,241$16.2M3.1%+1,884,501+68.3%AddedHistory
KALVKalVista Pharmaceuticals, Inc.COM1,338,568$15.8M3.0%+1,338,568NewHistory
IONSIonis Pharmaceuticals IncCOM330,000$15.7M3.0%+330,000NewHistory
CNTXContext Therapeutics Inc.COM7,419,355$14.9M2.8%+7,419,355NewHistory
FOLDAmicus Therapeutics, Inc.COM1,495,500$14.8M2.8%00.0%UnchangedHistory
OPTNOptiNose, Inc.COM13,727,097$14.3M2.7%+4,940,779+56.2%AddedHistory
ESPREsperion Therapeutics, Inc.COM5,791,594$12.9M2.5%−2,208,406−27.6%ReducedHistory
VYGRVoyager Therapeutics, Inc.COM1,601,527$12.7M2.4%+1,601,527NewHistory
OTLKOutlook Therapeutics, Inc.Stock1,701,510$12.6M2.4%+221,510+15.0%AddedHistory
AUTLAutolus Therapeutics plcSPON ADS3,441,667$12.0M2.3%+2,275,000+195.0%AddedHistory
JSPRJasper Therapeutics, Inc.COM NEW402,015$9.13M1.7%−5,535−1.4%ReducedHistory
OLMAOlema Pharmaceuticals, Inc.COM796,880$8.62M1.7%+796,880NewHistory
TERNTerns Pharmaceuticals, Inc.COM1,149,406$7.83M1.5%−160,569−12.3%ReducedHistory
VRDNViridian Therapeutics, Inc.COM500,000$6.50M1.2%−835,000−62.5%ReducedHistory
TCRXTScan Therapeutics, Inc.COM940,831$5.50M1.1%+940,831NewHistory
VTGNVistagen Therapeutics, Inc.COM1,529,338$5.32M1.0%−329,397−17.7%ReducedHistory
BBOTBridgeBio Oncology Therapeutics, Inc.CL A ORD SHS500,000$5.11M1.0%00.0%UnchangedHistory
PBYIPuma Biotechnology, Inc.COM1,486,544$4.85M0.9%+142,916+10.6%AddedHistory
KYTXKyverna Therapeutics, Inc.COM499,152$3.74M0.7%+349,152+232.8%AddedHistory
SYRESpyre Therapeutics, Inc.COM NEW134,612$3.16M0.6%+9,612+7.7%AddedHistory
ANABAnaptysbio, IncCOM25,000$626.5K0.1%−951,981−97.4%ReducedHistory
LXRXLexicon Pharmaceuticals, Inc.COM NEW30,000$50.4K<0.1%+30,000NewHistory

Sold out since Q1 2024 (9)

Positions held at the end of Q1 2024 that are gone from this filing.

Positions of Great Point Partners LLC sold out since Q1 2024
SecurityClassShares in Q1 2024Value in Q1 2024% of portfolio in Q1 2024History
ALPNAlpine Immune Sciences, Inc.COM1,128,499$44.7M7.0%History
APGEApogee Therapeutics, Inc.COM400,000$26.6M4.1%History
JBIOJade Biosciences, Inc.COM887,690$26.2M4.1%History
XENEXenon Pharmaceuticals Inc.COM456,148$19.6M3.1%History
DFTXDefinium Therapeutics, Inc.Stock2,000,000$18.8M2.9%History
OCULOcular Therapeutix, IncCOM1,728,723$15.7M2.5%History
ITCIIntra-Cellular Therapies, Inc.COM150,000$10.4M1.6%History
IMCRImmunocore Holdings plcADS115,000$7.47M1.2%History
ARVNArvinas, Inc.COM71,113$2.94M0.5%History